NO20060915L - Stabile modifikasjoner av tegaserodhydrogenmaleat - Google Patents

Stabile modifikasjoner av tegaserodhydrogenmaleat

Info

Publication number
NO20060915L
NO20060915L NO20060915A NO20060915A NO20060915L NO 20060915 L NO20060915 L NO 20060915L NO 20060915 A NO20060915 A NO 20060915A NO 20060915 A NO20060915 A NO 20060915A NO 20060915 L NO20060915 L NO 20060915L
Authority
NO
Norway
Prior art keywords
tegaserodhydrogen
maleate
stable modifications
crystalline forms
stable
Prior art date
Application number
NO20060915A
Other languages
English (en)
Inventor
Sabine Pfeffer
Christian Vitzling
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34135099&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20060915(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of NO20060915L publication Critical patent/NO20060915L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/4045—Indole-alkylamines; Amides thereof, e.g. serotonin, melatonin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/10—Laxatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Glass Compositions (AREA)
  • Liquid Crystal Substances (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Det krystallinske former fra tegaserodhydrogenmaleat. Videre beskrives deres anvendelse i farmasøytiske preparater som kan brukes ved behandling av irritabelt tarmsyndrom, gasa-esophageal reflux sykdom, funksjonell dyspepsi, kronisk konstipasjon og diaré. Videre beskrives fremstillingen av de krystalinske former.
NO20060915A 2003-07-24 2006-02-24 Stabile modifikasjoner av tegaserodhydrogenmaleat NO20060915L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US48963803P 2003-07-24 2003-07-24
PCT/EP2004/008281 WO2005014544A1 (en) 2003-07-24 2004-07-23 Stable modifications of tegaserod hydrogen maleate

Publications (1)

Publication Number Publication Date
NO20060915L true NO20060915L (no) 2006-04-24

Family

ID=34135099

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20060915A NO20060915L (no) 2003-07-24 2006-02-24 Stabile modifikasjoner av tegaserodhydrogenmaleat

Country Status (24)

Country Link
US (1) US20070112056A1 (no)
EP (2) EP1880992A1 (no)
JP (1) JP2006528609A (no)
KR (1) KR20060040710A (no)
CN (1) CN1826318A (no)
AR (1) AR045081A1 (no)
AU (1) AU2004263285A1 (no)
BR (1) BRPI0412830A (no)
CA (1) CA2532351A1 (no)
CO (1) CO5680418A2 (no)
EC (1) ECSP066306A (no)
IL (1) IL172914A0 (no)
IS (1) IS8321A (no)
MA (1) MA27935A1 (no)
MX (1) MXPA06000917A (no)
MY (1) MY137386A (no)
NO (1) NO20060915L (no)
NZ (1) NZ544596A (no)
PE (1) PE20050253A1 (no)
RU (1) RU2349585C2 (no)
SG (1) SG144944A1 (no)
TN (1) TNSN06024A1 (no)
TW (1) TW200510302A (no)
WO (1) WO2005014544A1 (no)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006045120A2 (en) * 2004-10-19 2006-04-27 Teva Pharmaceutical Industries Ltd. Purification of tegaserod maleate
JP2008528615A (ja) * 2005-01-31 2008-07-31 ノバルティス アクチエンゲゼルシャフト プロトンポンプ阻害剤により誘発され得る遅延した胃内容排出の処置のための５−ｈｔ４アゴニストの使用
CZ298399B6 (cs) * 2005-05-02 2007-09-19 Zentiva, A. S. Zpusob prípravy 2-[(5-methoxy-1 H-indol-3-yl) methylen]-N-pentylkarbazimidamidu (tegaserodu)
US20070112057A1 (en) * 2005-06-22 2007-05-17 Santiago Ini Polymorphic forms of tegaserod maleate
WO2007119109A2 (en) * 2005-10-06 2007-10-25 Medichem, S.A. Processes for preparing tegaserod maleate and pharmaceutical compositions containing it
GB0524668D0 (en) * 2005-12-02 2006-01-11 Novartis Ag Organic compounds
WO2007120924A1 (en) * 2006-04-17 2007-10-25 Teva Pharmaceutical Industries Ltd. Preparation of tegaserod maleate free of iodide
EP1956002A1 (en) * 2007-02-07 2008-08-13 Chemo Ibérica, S.A. New tegaserod maleate polymorphs and process for their preparation
AU2008252604A1 (en) * 2007-05-17 2008-11-27 Generics [Uk] Limited Process for the preparation of form A of tegaserod

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH01242588A (ja) * 1988-03-25 1989-09-27 Chiba Gosei Kenkyusho:Kk ７―シアノメチルチオアセトアミド―７α―メトキシ―３―（１―メチル―１Ｈ―テトラゾール―５―イル）チオメチル―３―セフェム―４―カルボン酸の結晶及びその製造方法
HUT64023A (en) * 1991-03-22 1993-11-29 Sandoz Ag Process for producing aminoguanidine derivatives and pharmaceutical compositions comprising such compounds
JPH08291140A (ja) * 1995-04-20 1996-11-05 Teikoku Chem Ind Corp Ltd 易吸収性結晶
RS50104B (sr) * 1998-08-21 2009-01-22 Novartis Ag., Nova oralna formulacija za 5-th4 agoniste ili antagoniste
EP1321142A1 (en) * 2001-12-21 2003-06-25 Novartis AG Solid pharmaceutical composition for oral administration of Tegaserod
CN1176077C (zh) * 2003-01-07 2004-11-17 江苏省药物研究所 马来酸替加色罗一水结晶
AU2003222439A1 (en) * 2003-03-25 2004-10-18 Hetero Drugs Limited Novel crystalline forms of tegaserod maleate
WO2005058819A2 (en) * 2003-12-16 2005-06-30 Teva Pharmaceutical Industries Ltd. Polymorphic forms of tegaserod base and salts thereof
US20050272802A1 (en) * 2004-04-22 2005-12-08 Sundaram Venkataraman Process for preparing form I of tegaserod maleate
US20070112057A1 (en) * 2005-06-22 2007-05-17 Santiago Ini Polymorphic forms of tegaserod maleate

Also Published As

Publication number Publication date
MA27935A1 (fr) 2006-06-01
IL172914A0 (en) 2006-06-11
PE20050253A1 (es) 2005-06-03
CO5680418A2 (es) 2006-09-29
AR045081A1 (es) 2005-10-12
TW200510302A (en) 2005-03-16
EP1651601A1 (en) 2006-05-03
TNSN06024A1 (en) 2007-10-03
IS8321A (is) 2006-02-22
MXPA06000917A (es) 2006-03-30
AU2004263285A1 (en) 2005-02-17
ECSP066306A (es) 2006-07-28
CA2532351A1 (en) 2005-02-17
US20070112056A1 (en) 2007-05-17
NZ544596A (en) 2009-01-31
RU2349585C2 (ru) 2009-03-20
MY137386A (en) 2009-01-30
KR20060040710A (ko) 2006-05-10
JP2006528609A (ja) 2006-12-21
EP1880992A1 (en) 2008-01-23
BRPI0412830A (pt) 2006-09-26
WO2005014544A1 (en) 2005-02-17
CN1826318A (zh) 2006-08-30
SG144944A1 (en) 2008-08-28
RU2006105481A (ru) 2007-09-20

Similar Documents

Publication Publication Date Title
NO20060915L (no) Stabile modifikasjoner av tegaserodhydrogenmaleat
NO20052595L (no) Sammensetninger anvendelige som inhibitorer av ROCK- og andre proteinkinaser.
MX2007014619A (es) Pirrolopiridinas de utilidad como inhibidores de proteina quinasa.
NO20080879L (no) HCV-NS3-proteaseinhibitorer
DE60332433D1 (de) Azolylaminoazine als proteinkinasehemmer
ATE468336T1 (de) Azolylaminoazine als proteinkinasehemmer
ATE365733T1 (de) Zusammensetzungen brauchbar als protein-kinase- inhibitoren
NO20063928L (no) Substituerte kinolinforbindelser
NO20025601L (no) Arylmetylaminderivater for anvendelse som tryptaseinhibitorer
NO20071095L (no) Hittil ukjente tiofenderivater
NO20024386L (no) Farmasöytiske sammensetninger av glycogenfosforylase- inhibitorer
NO20070224L (no) 2-karbamid-4-fenyltiazolderivater, fremstilling og terapeutisk anvendelse derav
DE60327999D1 (de) Azolylaminoazine als inhibitoren von proteinkinasen
MEP53708A (en) 3-z-[1-(4-(n-((4-methyl-piperazin-1-yl)-methylcarbonyl) -n-methyl -amino) -anilino)-1- phenyl-methylene] -6-methoxycarbonyl -2-indolinone -monoethanesulphonate and the use thereof as a pharmaceutical composition
NO20050851L (no) Kaspase-inhibitorer og anvendelser derav
WO2005000298A3 (en) 5-membered heterocycle-based p-38 inhibitors
NO20083523L (no) Sammensetning for vaginal anvendelse
NO20045042L (no) 7-aryl -3,9-diazabicyklo (3.1.1)non-6-en-derivater og deres anvendelse som renin. inhibitorer ved behandling av hypertensjon, kardiovaskulaere og nyresykdommer
DK1735296T3 (da) Materialer og fremgangsmåder til behandling af koagulationslidelser
EA200700673A1 (ru) Твердая фармацевтическая композиция, содержащая донепезила гидрохлорид
NO20011254D0 (no) Kopolymerblandinger og deres anvendelse som additiv til forbedring av kaldflyteegenskapene til mellomdestillater
NO20080392L (no) Pyrazolpyridinderivater som inhibitorer av beta-adrenergisk receptorkinase 1
NO20054346L (no) Sammensetninger og fremgangsmater for forebygging og behandling av endotoksinrelaterte sykdommer og tilstander
WO2001068569A3 (en) Il-8 receptor antagonists
WO2001072960A3 (en) Il-8 receptor antagonists

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application